GE (NYSE:GE) subsidiary GE Healthcare this week released it’s 2013 earnings, posting modest increases in profits for the 4th quarter and the full year amid relatively flat-to-declining sales.
J.P. Morgan Healthcare Conference
Renal denervation ‘highly unlikely’ for hypertension, says Medtronic study insider
The future of renal denervation in treatment of hypertension is shaky at best, according to 1 of the principal investigators involved with Medtronic’s disappointing clinical trial.
J.P. Morgan medtech wrap-up: Ups and downs from San Francisco
Diabetes: Insulet to hire 20 new sales reps as pediatric pump sales soar
Stryker affirms 2013 guidance, offers limited glimpse of Mako plans
NuVasive soars on estimates for Q4 and 2014
California medical device maker NuVasive Inc. (NSDQ:NUVA) is flying high today after raising its revenue projections for 2013 amid higher-than-expected 4th quarter sales.
HeartWare slides on missed Q4 prelims
HeartWare International (NSDQ:HTWR) said it expects to report 4th-quarter revenues of roughly $53 million, missing the consensus view on Wall Street of $58 million and sending its share price down sharply in pre-market trading.
Intuitive Surgical CEO responds to hubbub over adverse events
Diabetes: DexCom’s Q4 prelims beat The Street, shares tick down anyway
Dexcom Inc. (NSDQ:DXCM) shares closed down a hair today despite Wall Street-beating preliminary 4th-quarter sales numbers for the medical device company.
Boston Scientific stands fast on renal denervation
NxStage Medical’s Q4 prelims beat its own, Wall Street’s forecasts
NxStage Medical (NSDQ:NXTM) saw its stock price climb this morning after reporting preliminary 4th-quarter sales numbers that topped its own forecast and handily beat expectations on Wall Street.